| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/15/1999 | DE19745151A1 New N-2-Mercapto-3-phenyl-propionyl di:peptide derivatives |
| 04/15/1999 | CA2308123A1 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| 04/15/1999 | CA2306489A1 Benzothiophenes |
| 04/15/1999 | CA2306452A1 Use of growth differentiation factor-9 (gdf-9) as a contraceptive |
| 04/15/1999 | CA2306273A1 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| 04/15/1999 | CA2306077A1 Novel cycloalkenyl substituted compounds |
| 04/15/1999 | CA2305805A1 Compounds and methods |
| 04/15/1999 | CA2305751A1 Medicaments |
| 04/15/1999 | CA2305726A1 Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
| 04/15/1999 | CA2305709A1 Chlamydia protein, gene sequence and uses thereof |
| 04/15/1999 | CA2305707A1 Mutants of yeast cdc24p, defective in binding of the g-protein beta subunit |
| 04/15/1999 | CA2305685A1 101 human secreted proteins |
| 04/15/1999 | CA2305679A1 Novel lactam metalloprotease inhibitors |
| 04/15/1999 | CA2305414A1 Aryl thiophene derivatives as pde iv inhibitors |
| 04/15/1999 | CA2305413A1 Aryl furan derivatives as pde iv inhibitors |
| 04/15/1999 | CA2305182A1 Methods and compositions for the selective modification of nucleic acids |
| 04/15/1999 | CA2305045A1 Transgenic animals with knocked-in vec receptor genes and uses thereof |
| 04/15/1999 | CA2304826A1 5ht4 agonists and antagonists |
| 04/15/1999 | CA2304630A1 Taste masked formulations |
| 04/15/1999 | CA2304565A1 Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives |
| 04/15/1999 | CA2304466A1 Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity |
| 04/15/1999 | CA2304354A1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/15/1999 | CA2304116A1 Peptide-containing .alpha.-ketoamide cysteine and serine protease inhibitors |
| 04/15/1999 | CA2303449A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/15/1999 | CA2301569A1 Dosage form for aerosol administration |
| 04/15/1999 | CA2273274A1 Dosage forms having improved release properties |
| 04/14/1999 | EP0908459A1 5-HT4 Agonists and antagonists |
| 04/14/1999 | EP0908456A1 Pyrazole derivatives, their preparation and their use in drugs |
| 04/14/1999 | EP0908178A1 Partial liquid breathing of fluorocarbons |
| 04/14/1999 | EP0907738A1 Novel compounds |
| 04/14/1999 | EP0907737A1 Il-6 mutein |
| 04/14/1999 | EP0907666A1 Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| 04/14/1999 | EP0907661A1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS |
| 04/14/1999 | EP0907650A1 N- 4-(heteroarylmethyl)phenyl]-heteroarylamines |
| 04/14/1999 | EP0907649A1 Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| 04/14/1999 | EP0907632A1 Inhibition of matrix metalloproteases by substituted phenethyl compounds |
| 04/14/1999 | EP0907373A1 Use of il-12 and ifn-alpha for the treatment of infectious diseases |
| 04/14/1999 | EP0907370A1 Hla-a2.1 binding peptides and their uses |
| 04/14/1999 | EP0907369A1 Materials and methods for treatment of plaquing diseases |
| 04/14/1999 | EP0907361A1 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors) |
| 04/14/1999 | EP0810991B1 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists |
| 04/14/1999 | EP0794782A4 Cobalt schiff base compounds |
| 04/14/1999 | EP0767777B1 New salts of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with organic basic cations |
| 04/14/1999 | EP0754173B1 Method for purifying diacetyl rhein |
| 04/14/1999 | EP0748221B1 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors |
| 04/14/1999 | EP0698010B1 N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| 04/14/1999 | EP0679659B1 Cathepsin-l-specific inhibitor polypeptide |
| 04/14/1999 | EP0652879B1 1-azaadamantane derivatives as 5-ht4 agonists or antagonists and/or 5-ht3 antagonists |
| 04/14/1999 | EP0595924B1 Platelet activating factor antagonists |
| 04/14/1999 | EP0584285B1 Treatment of schizophrenia by cholinesterase inhibitors |
| 04/14/1999 | EP0510068B1 NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS |
| 04/14/1999 | CN1214048A Benzopyran derivatives having leukotriene-antagonistic action |
| 04/14/1999 | CN1214046A 4,5-dihydronaphth [1,2-C] isoxazoles and derivatives thereof having CNS activity |
| 04/14/1999 | CN1214043A Benzyl(idene)-lactam derivatives, their prepn. and their use as selective (ant) agaonists of 5-ht1A-and/or 5-ht1D receptors |
| 04/13/1999 | US5894070 Applying onto the hard tissue site an agent comprising a chitosan |
| 04/13/1999 | CA2150565C Psyllium drink mix compositions |
| 04/13/1999 | CA2116799C Solid form xerostomia product |
| 04/10/1999 | CA2249867A1 Osteoporosis compounds |
| 04/08/1999 | WO1999016888A2 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/08/1999 | WO1999016887A2 Compositions and methods for identifying pkb kinase inhibitors |
| 04/08/1999 | WO1999016877A1 Amino-terminally truncated rantes as chemokine antagonists |
| 04/08/1999 | WO1999016876A1 Amino-terminally truncated mcp-2 as chemokine antagonists |
| 04/08/1999 | WO1999016875A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells |
| 04/08/1999 | WO1999016784A1 Ras-binding protein (pre1) |
| 04/08/1999 | WO1999016771A1 Condensed benzothiopyranic compounds |
| 04/08/1999 | WO1999016755A1 Novel angiogenesis inhibitors |
| 04/08/1999 | WO1999016753A2 Tricyclic 3-oxo-propanenitrile compounds |
| 04/08/1999 | WO1999016752A1 β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USING |
| 04/08/1999 | WO1999016751A1 Benzamidine derivatives as factor xa inhibitors |
| 04/08/1999 | WO1999016750A1 Thrombin inhibitors |
| 04/08/1999 | WO1999016464A1 Modulation of nitric oxide production |
| 04/08/1999 | WO1999016461A1 Antistress agents and functional foods |
| 04/08/1999 | WO1999016460A2 Apolipoprotein e/growth factor complexes and methods of use |
| 04/08/1999 | WO1999016451A1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 04/08/1999 | WO1999016445A1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 04/08/1999 | WO1999016438A1 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| 04/08/1999 | WO1999016418A1 Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| 04/08/1999 | WO1999016409A2 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | WO1999016408A2 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | WO1999016406A2 Therapeutic method |
| 04/08/1999 | WO1999004752A9 Methods for treating skin pigmentation |
| 04/08/1999 | WO1999003882A3 Human leukocyte calcium activated potassium channel polypeptide |
| 04/08/1999 | WO1999003823A3 Novel polyamine analogues as therapeutic and diagnostic agents |
| 04/08/1999 | WO1998056913A9 Smad6 and uses thereof |
| 04/08/1999 | WO1998056910A9 DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE |
| 04/08/1999 | WO1998049972A3 Differential treatment of prosthetic devices |
| 04/08/1999 | DE19743435A1 Benzamidinderivate Benzamidine derivatives |
| 04/08/1999 | CA2305686A1 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/08/1999 | CA2305568A1 Benzamidinderivates |
| 04/08/1999 | CA2305017A1 Amino-terminally truncated mcp-2 as chemokine antagonists |
| 04/08/1999 | CA2304931A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | CA2304827A1 Amino-terminally truncated rantes as chemokine antagonists |
| 04/08/1999 | CA2304814A1 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | CA2304720A1 Apolipoprotein e/growth factor complexes and methods of use |
| 04/08/1999 | CA2304719A1 Modulation of nitric oxide production |
| 04/08/1999 | CA2304484A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells |
| 04/08/1999 | CA2304209A1 Ras-binding protein (pre1) |
| 04/08/1999 | CA2303832A1 Thrombin inhibitors |
| 04/08/1999 | CA2303830A1 Novel angiogenesis inhibitors |
| 04/08/1999 | CA2302027A1 Condensed benzothiopyranic compounds |